On November 3, 2025 Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune diseases and cancers, reported that the Company will present interim data from the Phase 1/2 clinical trial evaluating the safety, tolerability, and hematological effect of ulviprubart in patients with T cell large granular lymphocytic leukemia (T-LGLL) who suffer from neutropenia and/or anemia. The interim data will be presented in an oral presentation at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
T-LGLL is a hematological cancer characterized by clonally expanded CD8+ differentiated T cells resulting in neutropenia and anemia. Neutropenia can lead to frequent infections, a major cause of premature death in patients with T-LGLL, while anemia results in transfusion dependence in approximately one third of patients.
Oral Presentation Details:
Title: Clinical Activity, Tolerability, and Pharmacodynamics of Ulviprubart in Patients with T-Cell Large Granular Lymphocytic Leukemia: Interim Results of a Phase 1 Trial
Presenter: Salvia Jain, MD; Massachusetts General Hospital
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Novel Agents or Therapeutic Approaches in T-Cell Lymphoma
Session Date and Time: Monday, December 8, 2025, from 10:30 a.m. – 12:00 p.m. ET
Presentation Date and Time: Monday, December 8, 2025, from 11:30 a.m. – 11:45 a.m. ET
Location: OCCC – Tangerine Ballroom F1
Abstract Number: 779
About Ulviprubart
Ulviprubart (ABC008) is a first-in-class anti-KLRG1 antibody product candidate capable of selectively depleting highly cytotoxic T cells, while sparing naïve, regulatory and central memory T cells. Ulviprubart is designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia (T-LGLL). The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have each granted orphan drug designation to ulviprubart for the treatment of IBM. The FDA has also granted Fast Track designation for ulviprubart in IBM.
(Press release, Abcuro, NOV 3, 2025, View Source [SID1234659237])